Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crotalidae immune F(ab')2 (equine)
- Development stage
- Approved
- Lead developer
- Instituto Bioclon
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anavip is an equine-derived antivenin indicated for the management of adult and pediatric patients with envenomation from North American pit vipers, including rattlesnakes, copperheads, and cottonmouths. The active substance consists of venom-specific F(ab’)2 fragments of immunoglobulin G (IgG) purified from horse serum after immunization with pit viper venom. These antibody fragments bind to and neutralize venom toxins in the body, facilitating their redistribution away from target tissues and elimination. Anavip is administered intravenously as soon as possible after a qualifying snake bite to control local injury, coagulation abnormalities, or systemic signs of envenomation[1][2][4][5]. It can control most symptoms within 4 hours and may prevent further symptoms for up to 8 days[1][3]. Common side effects include itching, rash, nausea, headache, swelling in extremities or face; allergic reactions are possible due to its equine origin[1][5].
- Brand names
- Anavip
- Other names
- antivenin (Crotalidae) polyvalentCrotalidae Immune F(ab’)2snake antivenin
02
Targets
Crotalinae snake venom toxins
Beyond the preview
Go deeper on crotalidae immune F(ab')2 (equine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crotalidae immune F(ab')2 (equine).